DOI: 10.11648/j.ijcu.20261002.12 ISSN: 2640-1355

Silodosin in the Management of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: An Experts Perspective Study

Manjula Suresh, Krishna Manjunath
Show PDF Cite
Background: Benign prostatic hyperplasia (BPH) commonly causes lower urinary tract symptoms (LUTS), with α1-blockers as first-line therapy. Silodosin, due to its high uroselectivity and favorable tolerability, is increasingly used; this survey assesses clinician preferences, usage patterns, tolerability, and combination therapy practices in clinical practice. Methods: This cross-sectional survey was conducted among 97 urologists in India and used a validated 23-item questionnaire to assess treatment preferences, silodosin use, switching patterns, adverse events, combination therapies, and outcomes. Data were analyzed descriptively as frequencies and percentages. Results: The survey included 97 participants. A majority of clinicians (76%) preferred silodosin as the first-line α1-blocker for BPH management. Approximately 44% recognized all listed reasons for its use, including receptor selectivity, safety profile, and clinical benefits. Switching from tamsulosin to silodosin in 21–30% of patients due to inadequate symptom relief was reported by around 43% of clinicians. Marked clinical improvement with silodosin was observed by nearly 77%, while 54% reported no associated adverse drug reactions. Reduction in the risk of BPH-related surgery was identified as the key advantage of combination therapy by around 47% of clinicians. Preference for the silodosin and dutasteride combination to prevent disease progression was noted by 85% of respondents, and approximately 53% reported adding mirabegron to silodosin in 11–20% of patients. Conclusion: This survey highlights silodosin as an effective, well-tolerated, and first-line treatment for BPH and LUTS in clinical practice. Its high uroselectivity, favorable safety profile, and strong symptomatic relief support its use both as monotherapy and in combination with dutasteride or mirabegron in more complex cases. These findings underscore the need for further long-term studies to strengthen its role in BPH management.

More from our Archive